LEVERKUSEN (dpa-AFX) - German pharmaceutical and life sciences major Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday that its clinical stage cell therapy unit BlueRock Therapeutics LP's
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND